Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Paragraph IV Patent Certifications Winners and Losers Monthly Report - ResearchAndMarkets.com

November 11, 2019 GMT

DUBLIN--(BUSINESS WIRE)--Nov 11, 2019--

The “Para IV Winners and Losers - Monthly Report” has been added to ResearchAndMarkets.com’s offering.

The report highlights all the important opportunities for generic companies based on the latest Para IV litigation updates.

The analyses provides an insight into each product opportunity for generic companies in terms of:

The analyses is updated every time an important development as regards the product Para IV litigation happens. In other words, it is not only comprehensive but also updated. The report is published every month covering important updates on Para IV litigation.

Important Para IV events are following events related to Para IV litigations:

  • New Para IV applications filed
  • Litigation dismissals
  • Final judgments
  • Patent related opinions and judgments
  • PTAB updates

Sources of information:

  • US Courts documents
  • Company SEC filings / Annual Reports
  • PTAB

Products included in the Para IV Winners and Losers - Oct 2019 offering are shown below first by brand name and then by their generic name:

  • Oracea - Doxycycline
  • Chantix - Verenicline Tartrate
  • Sprycel - Dasatinib
  • Evoclin - Clindamycin Phosphate
  • Finacea - Azelaic Acid
  • Suprep - Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate
  • Sensipar - Cinacalcet Hydrochloride
  • Faslodex - Fulvestrant
  • Uloric - Febuxostat
  • Minivelle - Estradiol
  • Uceris - Budesonide
  • Isosulfan blue - Isosulfan blue
  • Bosulif - Bosutinib
  • Aubagio - Teriflunomide
  • Mydayis - Amphetamine Aspartate;Amphetamine Sulfate;Dextroamphetamine Saccharate; DextroamphetamineSulfate
  • Vasostrict - Vasopressin
  • Jardiance - Empagliflozin
  • Cerdelga - Eliglustat Tartrate
  • Evomela - Melphalan Hydrochloride
  • Synjardy XR - Empagliflozin; Metformin hydrochloride
  • Rhofade - Oxymetazoline hydrochloride
  • Rexulti - Brexpiprazole
  • Entresto - Sacubitril; Valsartan
  • Cleviprex - Clevidipine
  • Cabometyx - Cabozantinib S-Malate

For more information about this report visit https://www.researchandmarkets.com/r/3r6k14

View source version on businesswire.com:https://www.businesswire.com/news/home/20191111005533/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/11/2019 12:39 PM/DISC: 11/11/2019 12:39 PM